428 related articles for article (PubMed ID: 32026626)
21. EMAS position statement: Testosterone replacement therapy in the aging male.
Dimopoulou C; Ceausu I; Depypere H; Lambrinoudaki I; Mueck A; Pérez-López FR; Rees M; van der Schouw YT; Senturk LM; Simonsini T; Stevenson JC; Stute P; Goulis DG
Maturitas; 2016 Feb; 84():94-9. PubMed ID: 26614257
[TBL] [Abstract][Full Text] [Related]
22. An updated systematic review and meta-analysis of the effects of testosterone replacement therapy on erectile function and prostate.
Xu Z; Chen X; Zhou H; Ren C; Wang Q; Pan Y; Liu L; Liu X
Front Endocrinol (Lausanne); 2024; 15():1335146. PubMed ID: 38344665
[TBL] [Abstract][Full Text] [Related]
23. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
Sarosdy MF
Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
[TBL] [Abstract][Full Text] [Related]
24. Effects of intermission and resumption of long-term testosterone replacement therapy on body weight and metabolic parameters in hypogonadal in middle-aged and elderly men.
Yassin A; Almehmadi Y; Saad F; Doros G; Gooren L
Clin Endocrinol (Oxf); 2016 Jan; 84(1):107-14. PubMed ID: 26331709
[TBL] [Abstract][Full Text] [Related]
25. Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy.
Ide V; Vanderschueren D; Antonio L
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33375030
[TBL] [Abstract][Full Text] [Related]
26. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.
Marks LS; Mazer NA; Mostaghel E; Hess DL; Dorey FJ; Epstein JI; Veltri RW; Makarov DV; Partin AW; Bostwick DG; Macairan ML; Nelson PS
JAMA; 2006 Nov; 296(19):2351-61. PubMed ID: 17105798
[TBL] [Abstract][Full Text] [Related]
27. Outcomes of Prostate Biopsy in Men with Hypogonadism Prior or During Testosterone Replacement Therapy.
Shoskes DA; Barazani Y; Fareed K; Sabanegh E
Int Braz J Urol; 2015; 41(6):1167-71. PubMed ID: 26742976
[TBL] [Abstract][Full Text] [Related]
28. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
[TBL] [Abstract][Full Text] [Related]
29. Clinical and laboratoristic strategy in late onset hypogonadism.
Lombardo F; Lupini C; Meola A; Pallotti F; Gandini L; Lenzi A
Acta Biomed; 2010; 81 Suppl 1():85-8. PubMed ID: 20518196
[TBL] [Abstract][Full Text] [Related]
30. Testosterone replacement therapy in hypogonadal male patients with hypogonadism and heart failure: a meta-analysis of randomized controlled studies.
Cannarella R; Barbagallo F; Crafa A; Mongioì LM; Aversa A; Greco E; Condorelli RA; LA Vignera S; Calogero AE
Minerva Urol Nephrol; 2022 Aug; 74(4):418-427. PubMed ID: 33781026
[TBL] [Abstract][Full Text] [Related]
31. The effect of physiotherapy in addition to testosterone replacement therapy on the efficiency of the motor system in men with hypogonadism.
Bacevičienė R; Valonytė L; Ceponis J
Medicina (Kaunas); 2013; 49(2):71-7. PubMed ID: 23888342
[TBL] [Abstract][Full Text] [Related]
32. Effects of long-term testosterone replacement therapy, with a temporary intermission, on glycemic control of nine hypogonadal men with type 1 diabetes mellitus - a series of case reports.
Saad F; Yassin A; Almehmadi Y; Doros G; Gooren L
Aging Male; 2015; 18(3):164-8. PubMed ID: 26075537
[TBL] [Abstract][Full Text] [Related]
33. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
Raynaud JP; Gardette J; Rollet J; Legros JJ
BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
[TBL] [Abstract][Full Text] [Related]
34. Testosterone replacement therapy for late-onset hypogonadism: current trends in Korea.
Ko YH; Kim JJ
Asian J Androl; 2011 Jul; 13(4):563-8. PubMed ID: 21572448
[TBL] [Abstract][Full Text] [Related]
35. Male hypogonadism : an update on diagnosis and treatment.
Darby E; Anawalt BD
Treat Endocrinol; 2005; 4(5):293-309. PubMed ID: 16185098
[TBL] [Abstract][Full Text] [Related]
36. Testosterone replacement therapy can increase circulating endothelial progenitor cell number in men with late onset hypogonadism.
Liao CH; Wu YN; Lin FY; Tsai WK; Liu SP; Chiang HS
Andrology; 2013 Jul; 1(4):563-9. PubMed ID: 23653307
[TBL] [Abstract][Full Text] [Related]
37. Long-term testosterone therapy in type 2 diabetes is associated with reduced mortality without improvement in conventional cardiovascular risk factors.
Hackett G; Cole N; Mulay A; Strange RC; Ramachandran S
BJU Int; 2019 Mar; 123(3):519-529. PubMed ID: 30216622
[TBL] [Abstract][Full Text] [Related]
38. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS).
Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
J Sex Med; 2011 Nov; 8(11):3204-13. PubMed ID: 21834870
[TBL] [Abstract][Full Text] [Related]
39. ISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of late-onset hypogonadism in males: scientific background and rationale.
Lunenfeld B; Saad F; Hoesl CE
Aging Male; 2005 Jun; 8(2):59-74. PubMed ID: 16096160
[TBL] [Abstract][Full Text] [Related]
40. Obstructive Sleep Apnea Is Associated With Polycythemia in Hypogonadal Men on Testosterone Replacement Therapy.
Lundy SD; Parekh NV; Shoskes DA
J Sex Med; 2020 Jul; 17(7):1297-1303. PubMed ID: 32307242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
